Precision Medicine

The explosion of genetic and molecular medicine has produced mountains of options and evidence. Conversely, there is often an alarming lack of evidence. This is where we come in.

We help you manage the flood of tests and drugs that emerge in this category daily. Accessed through the Hayes Knowledge Center, our comprehensive Precision Medicine solution focuses on thousands of genetic, genomic, and molecular diagnostic tests and precision medicine therapies addressing the questions our clients most frequently ask:

  • Will testing change patient management for this indication?
  • If so, what tests and/or therapies should I use?
  • Should we cover testing and/or therapies?
  • Can we manage these services internally?

DCISionRT (Prelude Corp.)

This report evaluates the analytical validity, clinical validity, and clinical utility of the DCISionRT (Prelude Corp.) test.

clonoSEQ (Adaptive Biotechnologies)

This report evaluates the analytical validity, clinical validity, and clinical utility of the clonoSEQ test (Adaptive Biotechnologies) specific to U.S. Food and Drug Administration (FDA)-cleared intended use.

PrismRA (Scipher Medicine)

This report evaluates the analytical validity, clinical validity, and clinical utility of the PrismRA test. According to the laboratory, the PrismRA molecular signature test identifies which patients with rheumatoid arthritis (RA) are unlikely to respond to tumor necrosis factor-ɑ inhibitor (TNFi) therapies to help guide …

DecisionDx-Melanoma

This report evaluates the analytical validity, clinical validity, and clinical utility of the DecisionDx-Melanoma test.